Montreal / London / Baltimore / Chicago / Rotterdam / /
Company
QLT Inc. / Ditta Zobor / /
Currency
IDR / /
Facility
Ophthalmology Wilmer Eye Institute / University of Tübingen / Netty Dorrestijn Montreal Children's Hospital / Johns Hopkins University / The Johns Hopkins University / Phase Ib Clinical Trial Wilmer Eye Institute / Rotterdam Eye Hospital / McGill University Health Centre / Stacey Seabrook Moorfields Eye Hospital / Anita-Maria Raidt Chicago Lighthouse / /
office of Research and Administration / McGill University Health Centre / School of Medicine / Clinical Trial Wilmer Eye Institute / Netty Dorrestijn Montreal Children's Hospital / Rotterdam Eye Hospital / Stacey Seabrook Moorfields Eye Hospital / Louise Williams Center for Ophthalmology / University of Tübingen / Johns Hopkins University / U.S. Securities and Exchange Commission / NHS / Ophthalmology Wilmer Eye Institute / /
Person
Gerald A. Fishman / Rupert Strauss / David Saperstein / Hendrik P.N. Scholl / Martin Lindeman / Kristen Bowles / Tobias Peters / Jonas Tapia / Michel Michaelides / Ronald Schuchard / Chris Timms / Anthony T. Moore / Caroline Jordaan / Barbara Wilhelm / Robert Koenekoop / Robert K. Koenekoop / Eunice Esteban / Chantal Dupuis / Leah Wood / Anna Maria Krijnen / Carol White / Yulia Wolfson / Esther Hofland / Gerald Fishman / Anthony Moore / Lisa Liberto / Frederick Collison / Simona Esposti / Howard Ying / Emily C. Fletcher / /
Position
general economic conditions / principal investigator / Professor / Consultant / Private / /
Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT On behalf of the RET IRD 02 Study Group: Hendrik P.N.